bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more
bioMérieux S.A (BMXMF) - Total Liabilities
Latest total liabilities as of June 2025: $1.43 Billion USD
Based on the latest financial reports, bioMérieux S.A (BMXMF) has total liabilities worth $1.43 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
bioMérieux S.A - Total Liabilities Trend (2005–2024)
This chart illustrates how bioMérieux S.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
bioMérieux S.A Competitors by Total Liabilities
The table below lists competitors of bioMérieux S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Norsk Hydro ASA
OTCQX:NHYKF
|
USA | $101.20 Billion |
|
Fiberhome Telecommunication Technologies Co Ltd
SHG:600498
|
China | CN¥27.82 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥13.53 Billion |
|
Ryman Hospitality Properties Inc
NYSE:RHP
|
USA | $4.99 Billion |
|
Scout24 AG
PINK:SCOTF
|
USA | $737.38 Million |
|
Shenzhen Techwinsemi Technology Co. Ltd.
SHE:001309
|
China | CN¥7.58 Billion |
|
CG Power and Industrial Solutions Limited
NSE:CGPOWER
|
India | ₹39.20 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down bioMérieux S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how bioMérieux S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for bioMérieux S.A (2005–2024)
The table below shows the annual total liabilities of bioMérieux S.A from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.56 Billion | +3.45% |
| 2023-12-31 | $1.51 Billion | -2.38% |
| 2022-12-31 | $1.54 Billion | +7.04% |
| 2021-12-31 | $1.44 Billion | -0.30% |
| 2020-12-31 | $1.45 Billion | -5.29% |
| 2019-12-31 | $1.53 Billion | +10.17% |
| 2018-12-31 | $1.39 Billion | +10.61% |
| 2017-12-31 | $1.25 Billion | -10.96% |
| 2016-12-31 | $1.41 Billion | +10.74% |
| 2015-12-31 | $1.27 Billion | +6.65% |
| 2014-12-31 | $1.19 Billion | +28.25% |
| 2013-12-31 | $929.30 Million | +46.81% |
| 2012-12-31 | $633.00 Million | -3.92% |
| 2011-12-31 | $658.80 Million | +39.40% |
| 2010-12-31 | $472.60 Million | +4.26% |
| 2009-12-31 | $453.30 Million | -9.48% |
| 2008-12-31 | $500.80 Million | +26.11% |
| 2007-12-31 | $397.10 Million | +3.93% |
| 2006-12-31 | $382.10 Million | -6.26% |
| 2005-12-31 | $407.60 Million | -- |